Dual Benefit of TGFB Inhibition on Tumor Control in the Context of Radiotherapy for Breast Cancer Brain Metastases
Abstract
This project evaluates whether transforming growth factor beta (TGF) inhibition during radiation therapy (RT) to breast cancer brainmetastases (BCBM) provides greater therapeutic benefit than RT alone using a robust proof-of-concept therapeutic protocol in combination with innovative functional imaging. Successful demonstration that TGF inhibition increases durable RT response that may augment immunotherapy in preclinical BCBM models would provide a strong rationale for trials of clinically viable drugs that block TGFsignaling with gamma-knife stereotactic radiosurgery (GKSRS) for women with metastatic disease. We incorporate molecular imaging of active TGF to assess target levels, drug delivery, therapeutic response via tumor metabolism, and identify potential immune mediated responses that will enable rapid clinical translation of combined RT and TGF inhibitory drug regimens.
Document Details
- Document Type
- Technical Report
- Publication Date
- Apr 01, 2020
- Accession Number
- AD1114587
Entities
People
- Mary H. Barcellos-hoff
Organizations
- University of California Regents